GlassScriptPhysician profile
Jonathan M Martin
NPI 1174908230
$2,756.63
in general payments reported to CMS, 2019-2025
18 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $84.18 · 2021: $28.58 · 2022: $87.04 · 2023: $152 · 2024: $857 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,021.89 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $270.41 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $219.21 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $181.66 | 2024-2025 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $171.34 | 2024-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $140.27 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.43 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $104.65 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $100.45 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $90.20 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $74.10 | 2024 | |
| Axsome Therapeutics, INC. | $64.65 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $61.78 | 2024-2025 | Cobenfy |
| Indivior INC. | $53.07 | 2022-2024 | Sublocade, Perseris |
| Biogen, INC. | $28.53 | 2025 | Zurzuvae |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.49 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $13.97 | 2023 | Rotarix, Pediarix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $10.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.